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Polymorphisms of genes encoding key factors for the control and activation of inﬂammatory response
and coagulation cascade regulation may play a role in genetic susceptibility to acute myocardial infarc-
tion (AMI). This study sought to analyze the effect of TNF 308G/A and pro-thrombin (FII) 20210G/A
polymorphisms on the laboratory parameters of young patients affected by AMI. Results indicated that
TNF 308A positive genotype frequencies were increased in these patients and that a genetically deter-
mined higher production of TNF-a is associated in young subjects to a more severe cardiac damage as
depicted by higher levels of troponin, Creatine kinase-MB Isoenzyme (mCK-MB) and a signiﬁcant
increased plasma ﬁbrinogen levels. Similar and probably additive effects on might have a genetically
determined increased production of pro-thrombin even if no signiﬁcant differences in genotype frequen-
cies of pro-thrombin (FII) 20210G/A polymorphisms were observed in this study. All together these
results, indicating the relationship among genetically determined TNFa and FII production and increased
levels of tissue damage markers of AMI, suggest that a complex genetic background, might be involved in
susceptibility to AMI in young men inﬂuencing the extension and severity of the disease.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Acute myocardial infarction (AMI) the leading cause of mortal-
ity and morbidity in industrialized countries is a common outcome
of coronary atherosclerosis. As other multifactorial disease, AMI
probably involves many different gene variants that might interact
to result in an additive or a synergistic co-effect. Young adults are a
relatively small proportion of patients who experience AMI [1].
They have some distinct characteristics compared to older patients
as young people are more likely to have normal coronary arteriesll rights reserved.
aPTT, time (in seconds) of
otransferase; CHD, coronary
, factor II (pro-thrombin); FV,
; IL-6, interleukin-6; IL-10,
CK-MB, creatine kinase-MB;
nucleotide polymorphisms;
nslated region.
iopathology and Medical and
Tukory 211, 90134 Palermo,
loredanavaccarino@libero.it[2]. Although the exact pathogenetic mechanism of AMI in young
patients remains unknown it has been proposed that thrombus
formation due to atherosclerotic plaque rupture or erosion is, al-
ways, the main mechanism [3].
The importance of genetic factors seems to be particularly rele-
vant in younger subjects, where it is assumed that the genetic
background inﬂuences the susceptibility of these subjects to envi-
ronmental risk factors for AMI identiﬁed in the general population.
In particular a prominent role of genetic factors in the onset of this
disease has been documented in twins and family based studies
[4].
Recently a number of candidate genes and chromosomal loci
have been identiﬁed to be associated with the susceptibility to
myocardial infarction and a majority of these genes have been
implicated in the processes of inﬂammation [5,6]. The single nucle-
otide polymorphisms (SNPs) present in the genes CD14 (159 C/T),
TNFa (308 G/A), IL-1a (889 C/T), IL-6 (174 G/C), PSMA6 (8 C/
G), and PDE4D (SNP83 T/C, respectively), were found to be associ-
ated with increased risk of cardiovascular diseases in different pop-
ulations [7–12]. In addition previous studies have shown that
polymorphisms of genes encoding key factors for the control and
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ceptibility to AMI in young men [13,14].
In particular the pleiotropic pro-inﬂammatory cytokine tumor
necrosis factor (TNF)-alpha, lying at the telomeric end of the class
III region of the human leukocyte antigen (HLA) [15–18]. Play a
central role in the inﬂammatory responses with multiple biologic
activities.
Wilson and his colleagues [19] ﬁrst reported the bi-allelic poly-
morphism within the 50 genomic region of the TNF-a gene pro-
moter at position 308 (308G? A; rs1800629). Carrying the A
allele enhances transcriptional activity and is reported to be asso-
ciated with higher levels of circulating TNF-a [20,21]. Serum levels
of TNF-a is elevated in coronary heart disease (CHD) patients and
may modify the risk for developing coronary events since it affects
endothelial cell hemostatic function [22] and in a recent metanal-
ysis [23] it has been demonstrated that this polymorphism might
be a risk factor for coronary heart disease.
Moreover congenital or acquired mutations located on genes
coding for antithrombin III, protein C, protein S, factor V Leiden
(FV) and prothrombin (FII), normally associated to the occurring
of deep venous thrombosis, were also inconstantly found in pa-
tients with arterial thrombosis. Recent observations stressed the
hypothesis that mutations of FV and FII may be risk factors for
acute myocardial infarction [24–28].
The prothrombin gene is organized in 14 exons, separated by 13
introns with the 50 upstream untranslated region (UTR) and the 30-
UTR which may play regulatory roles in gene expression [29,30].
One genetic variation in the 30-UTR region of the prothrombin gene
is the G to A transition at nucleotide position 20210, at or near the
cleavage site of the mRNA precursor to which poly A is added. This
was termed as the factor II G 20210A mutation. The prevalence of
carriers of factor II 20210G/A substitution (rs1799963) in healthy
Northern Europeans is 1.7% whereas in Southern Europeans the
prevalence is nearly double (3%) [31].
In 1996, Poort et al. [29] reported that the 20210G/A single
nucleotide polymorphism (SNP) is associated with an increased
risk of venous thrombosis. Several studies conﬁrmed this initial
observation both in venous thrombosis and arterial disease [30,32].
In the present study, we analyze the frequencies of polymor-
phisms 20210G/A of FII and 308G/A of the promoter region of
TNF-a in a group of Sicilian patients aged <46 years affected by
AMI and evaluate the effect of these polymorphisms on the blood
levels of myocardial tissue damage and clotting markers, to evalu-
ate the possibility to use typing of these polymorphisms in associ-
ation with selected haematochemical parameters in prognostic
evaluation of these patients.2. Materials and methods
2.1. Subjects
In this study, we analyzed two cohorts of men affected by acute
myocardial infarction (AMI) and unrelated controls matched for
age and sex. The cohort comprised 60 young male patients (age
range 23–46 years) affected by acute myocardial infarction, con-
secutively admitted to the Cardiac Unit of Palermo University Hos-
pital in the last year, and 130 healthy age and gender matched
controls, all living in western Sicily. The diagnosis of acute myocar-
dial infarction was based on standard laboratory (troponin I great-
er than decision limit, 3.0 ng/mL) [33] ﬁndings, typical
electrocardiographic changes and conﬁrmed by echocardiography
and coronary angiography. According to the Helsinki declaration
and to local ethical committee recommendations for the observa-
tional studies, written informed consent for enrolling in the study
and for personal data management was obtained from all thesubjects. Blood samples from patients were collected 48 h from
symptoms, transported and processed promptly according to pre-
analytical recommendations [34].
2.2. Biochemical and hematological analyses
Cardiac markers were examined by automatic analyzers in the
fresh blood sample collected 48 h after myocardial infarction. The
activity of aspartate aminotransferase (AST) and levels of CK-MB
isoenzyme (CK-MBmass, mCK-MB) and Troponin I were quantiﬁed
by routine chemical and immunochemichal clinical laboratory
methods (Biochemical automatic analyzer: Modular P and E,
Roche, Basel, Switzerland); haemochromecytometric test was per-
formed by analyzer Sismex 9500, coagulation tests: prothrombin
activity (PT), time of activated partial thromboplastin (aPTT),
ﬁbrinogen Clauss by automatic analyzer Futura Advance.
2.3. DNA genotyping
Genomic DNA was isolated by a standard method using protein-
ase K digestion followed by a standard salting-out technique [16].
2.3.1. Molecular analysis of alleles at the 308 nucleotide
(308G? A) of TNF-a gene
The 308G/A polymorphism (rs1800629) of TNF-a was identi-
ﬁed using a modiﬁcation of PCR-Restriction Fragment Length Poly-
morphism assay described by Galbraith and Pandey [35]. Brieﬂy,
0.5 lM of forward and reverse primers (50AGG CAA TAG GTT TTG
AGG GCC AT 30 and 50GGC GGG GAT TTG GAA AGT T 30) were mixed
to 5–10 ng of DNA template, with a ﬁnal concentration of 0.2 U Taq
DNA polymerase (Perkin Elmer BioSystem, Rome, Italy), 200 lM of
each deoxynucleotide and 1X reaction buffer. PCR was performed
for 35 cycles at 94 C, 58 C and 72 C for 35 s, respectively. Restric-
tion enzyme digestion with Ncol (M-Medical, Milan, Italy) of the
PCR ampliﬁed product (159 bp) and subsequent electrophoresis
on a 2–5% agarose gel discriminated between the two alleles;
308A showed two fragments of 146 bp and 13 bp, while 308G
was undigested and resulted in a single band of 159 bp. Heterozy-
gous individuals were detected by the presence of all the three
fragments.
2.3.2. Molecular analysis of alleles at the 20210 nucleotide
(20210G? A) of prothrombin (factor II) gene
The identiﬁcation of the alleles in the polymorphic site of Factor
II was obtained by Real Time PCR using TaqMan Pre-Developed As-
say Reagents for Allelic Discrimination essays optimized by Ap-
plied Biosystems on a 7300 Real Time PCR System as previously
described [36]. Brieﬂy, 10 ng of DNA for each sample were used
in a PCR reaction, containing 1X optimized master mix and 1X spe-
ciﬁc primers/probes mix assay, according to manufactory protocol
in a ﬁnal volume of 25 ll. Two identical probes, except for the cen-
tral nucleotide that speciﬁcally recognizes the single nucleotide
polymorphism (SNP) were used, each one labeled at the 50 extrem-
ity with different dyes (for the wild-type allele the ﬂuorochrome
FAM, and the ﬂuorochrome VIC for probe speciﬁc for minor allele)
and at the 30 extremity with a quencher dye, that in this case was
the Minor Groove Binder (MGB) dye. Then, the ampliﬁcation was
performed in 7300 Real-Time ABI Prism PCR System (Applied Bio-
systems, USA), using a standard ampliﬁcation protocol (1 cycle of
20 at 50 C; 1 cycle of 100 at 95 C and 40 cycles of 1500 at 95 C plus
1500 at 60 C), and the results available in the report sheet of 7300
System SDS v1.3 Software. Finally, samples were graphically
grouped in 3 genotypic clusters, easily recognizable in the Allelic
Discrimination plot on the basis of the two probe’s ﬂuorescence
intensity emissions, whereas the uncertain cases were also evalu-
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on the component’s sheet.2.4. Statistical analysis
The Hardy–Weinberg equilibrium was conﬁrmed by Pearson’s
test (goodness of ﬁt between the observed and expected genotype
(32 tables) and allele (22 tables) frequencies). Fisher’s exact
tests were performed to calculate signiﬁcant different genotype
or allelic distributions between patients with acute myocardial
infarction and healthy controls. Odds ratio and 95% of conﬁdence
intervals were calculated with Woolf’s approximation to quantify
the risk in carriers of minor allelic variants. Differences in quanti-
tative and qualitative data were analyzed using formal statistical
tests (ANOVA followed by t-Student test). Differences were consid-
ered signiﬁcant when p < 0.05.3. Results
In previous studies we have demonstrated that proinﬂamma-
tory gene variants determine an increased individual’s risk for
myocardial infarction [14]. Table 1 shows the analysis of genotypic
frequencies of the single nucleotide polymorphisms of TNF
(308G/A) an of the prothrombin (factor II, FII 20210G/A) among
the 60 male patients and 130 healthy controls. Both patient’ and
control’ genetic frequencies ﬁt the Hardy–Weinberg equilibrium
for both the two SNPs. We observed a signiﬁcant increase of fre-
quency of genotypes positive for the minor allele (A) of 308G/A
SNP (p = 0.0018), that are represented with a percentage of 36.7%
among patients, against 14.6% among the healthy controls
(p = 0.0048, odds ratio 4.00; 95% conﬁdence interval: 1.51–10.56).
In addition a not signiﬁcant increase of the percentage of subject
bearing the 20210A allele of the factor II gene (8.3% vs 6.9%).
As well known AMI is diagnosed using some serum speciﬁc
markers as Cardiac troponin I (CTnI) and Creatine kinase-MB Isoen-
zyme protein (mCK-MB). Table 2 reports data on the effect of TNF
308G/A and FII 20210G/A polymorphisms on the levels of these
haematochemical markers, on the levels of Aspartate Transpeptid-
ases (AST) measurement, nowadays considered obsolete for this
purpose and leukocytes. Stratifying haematochemical data accord-
ing the two SNP genotypes the higher levels of CTnI were observed
in subject bearing the TNF-a 308A or the FII 20210A alleles.
On the other hand subjects positive for 308A shows the higher
levels of mCK-MB whereas the FII 20210A ones shows the higher
levels of leucocytes. The analysis of the effect of 308G/A TNFa
and 20210G/A factor II genotypes on coagulation parameters,
showed a signiﬁcant increasing of plasma ﬁbrinogen levels and
of circulating platelets concentration in young men with acute
myocardial infarction homozygous or heterozygous for 308A al-
lele TNFa (Table 3). A similar pattern of ﬁbrinogen concentration
was observed in subjects bearing Factor II GA or AA genotypes.Table 1
308G/A TNF and 20210G/A FII genotype frequencies in 60 young patients affected by ac
Genotypes AMI % Heal
TNF SNP 308G/A GG 38 63.4 111
AG 20 33.3 17
AA 2 3.3 2
AG/AA 22 36.7 19
Factor II SNP 20210G/A GG 55 91.7 121
AG 4 6.6 7
AA 1 1.7 2
AG/AA 5 8.3 94. Discussion
Signs of a systemic inﬂammatory response such as fever, leuco-
cytosis and elevated acute phase reactants are frequently observed
in patients with AMI and CHD. In patients with extensive myocar-
dial infarction a pronounced inﬂammatory response may further
complicate the clinical course [17]. After acute myocardial infarc-
tion, systemic inﬂammatory response is associated with the in-
creases in plasma cytokines, such as TNF-a, interleukin-6 (IL-6)
and IL-10, in myocardium and blood. TNF-a as a pro-inﬂammatory
cytokines and can cause severe damage to cardiomyocytes and
suppress cardiac function [36].
In addition excessive thrombin generation has been described
in individuals at high risk of fatal CHD [37]. It seems biologically
plausible that the higher prothrombin levels related to the
20210A variant may also confer an increased risk of arterial
disease.
Results reported in Table 1 conﬁrm reports from previous re-
searches [13,14] on the role of TNF 308A allele in AMI and sug-
gest that this gene variant might be an AMI risk factor for young
men but do not allow to conﬁrm the association between FII
20210A allele and AMI. To date, actually, studies attempting to an-
swer this question have yielded conﬂicting results. In some reports,
being a carrier of the mutation was associated with an increased
risk of acute myocardial infarction (AMI) [38,39]. Nevertheless,
prospective studies failed to establish any association between
the 20210A allele and AMI [40].
As reported in Table 1 the cumulative frequencies of genotypes
positive for Prothrombin 20210A allele in our patients and control
populations are almost doubled respect the published frequencies
for the South Europe. These differences are probably due to the pa-
tient and control populations sampling (young men). So our sub-
jects cannot be considered representative of the general
population. On the other hand the North to South gradient in dis-
tribution of genotypes in Caucasians was established at 50N lati-
tude [8]. Sicily is at very South of this distribution so one could
speculate that the frequency of Prothrombin 20210A allele might
be further increased in our population. In all cases a different
and larger population sample is necessary to determine Prothrom-
bin 20210G/A genotype and allele frequencies in general Sicilian
population.
Our data indicate that TNF 308G/A and FII 20210G/A polymor-
phisms impinge upon the levels of haematochemical markers asso-
ciated to acute myocardial infarction. As well known the cardiac
form of Cardiac troponin I (CTnI) levels are routinely measured
for diagnosing acute myocardial infarction. Cardiac troponin mea-
surements also provide information concerning prognosis and the
effect of early intervention in patients with acute coronary syn-
dromes. Similarly measurement of concentration of Creatine ki-
nase-MB Isoenzyme protein (mCK-MB) represent an important
marker of degree of myocardial damage immediately after AMI
[41]. On the other hand Cardiac tissue necrosis induces anute myocardial infarction (AMI) and 130 health sex and age matched controls.
thy controls % O.R. 95%C.I. p
85.4 0.29 0.14–0.62 0.0018
13.1 3.43 1.58–7.45 0.0026
1.5 1.86 0.26–13.57 n.s
14.6 4.00 1.51–10.56 0.0048
93.1 0.44 0.11–1.84 n.s.
5.4 1.26 0.35–4.46 n.s.
1.5 1.09 0.10–12.21 n.s.
6.9 1.22 0.39–3.82 n.s.
Table 2
Evaluation of blood data (Mean ± D.S.) of 60 young patients affected by acute
myocardial infarction (AMI) according to tumor necrosis factor a (TNFa) 308G/A
and prothrombin (factor II) 20210G/A genotypes.
Genotypes CTnI CK-MBm AST WBC NEUT
TNF GG
(38)
12.1 ± 5.4 23.5 ± 9.2 53.9 ± 43.8 9.2 ± 1.6 6.05 ± 1.7
TNF GA/AA
(22)
20.8 ± 7.6 39.7 ± 11.1 61.7 ± 30.8 9.2 ± 5.2 6.9 ± 5.1
p <0.0001 <0.0001 n.s. n.s. n.s.
Factor II
GG (55)
11.2 ± 3.6 26.5 ± 8.7 44.33 ± 21.9 8.7 ± 4.8 5.7 ± 2.0
Factor II
GA/AA
(5)
19.9 ± 6.7 31.4 ± 9.2 75.9 ± 41.1 13.7 ± 3.2 9.33 ± 4.4
p 0.0456 n.s n.s. 0.0244 n.s.
Table 3
Evaluation of haematic coagulation marker proﬁle (Mean ± D.S.) of 60 young patients
affected by acute myocardial infarction (AMI) according to tumor necrosis factor a
(TNFa) 308G/A and to prothrombin (factor II) 20210G/A genotypes.
Genotypes INR APTT Fibrinogen mg/
dL
PLT  109/L
TNF GG (38) 1.01 ± 0.07 29.1 ± 10.1 364.5 ± 41.1 181.1 ± 46.2
TNF GA/AA (22) 1.03 ± 0.16 23.8 ± 12.2 418.15 ± 113.0 275.0 ± 46.9
p n.s n.s 0.0110 <0.0001
Factor II GG (55) 0.89 ± 0.10 29.1 ± 15.6 315.7 ± 39.7 295.0 ± 56.3
Factor II GA/AA
(5)
1.00 ± 0.23 29.0 ± 25.3 412.7 ± 95.2 250.0 ± 61.1
p n.s. n.s. 0.0017 n.s
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crease of circulating leucocytes due to neutrophil mobilization.
Inﬂammatory response is an important feature of acute coronary
syndromes and myocardial infarction. In AMI signs of inﬂamma-
tion are well known and elevated levels of acute phase reactants
have been shown to be associated with a worse short- and long-
term prognosis [17,42]. Our data strongly suggest that a genetically
determined higher production of TNF-a is associated in young sub-
jects to a more severe cardiac damage in AMI as depicted by higher
levels of troponin and mCK-MB.
A similar and probably additive effect might have a genetically
increased production of prothrombin. On the other hand consider-
ing the small number of patients (5 subjects) positive for the
20210A allele and the relative variability of results obtained in this
small group of subjects the deﬁnition of weight of this genetic var-
iant on haematochemichal marker necessitate further studies on
larger group of subjects.
Fibrinogen is themajor coagulation protein in blood bymass, the
precursor of ﬁbrin, and an important determinant of blood viscosity
and platelet aggregation [24,43]. Our data indicate that subjects
bearing proinﬂammatory or procoagulant genotypes have the high
plasma ﬁbrinogen. As well known starting from the seminal paper
by Hashmi et al. [44], high ﬁbrinogen levels are predictor of coro-
nary artery lesions, more recently it has been reported that plasma
ﬁbrinogen level may predict critical coronary artery stenosis in
young adults with myocardial infarction [45]. In this view our data
seem to suggest that the typing of the studied SNP of TNF-a and of
FII associated to plasma ﬁbrinogen measurement might be an use-
ful tool to the prognostic evaluation of IMA in young subjects.5. Conclusions
All together the results of the present study, indicating the rela-
tionship among genetically determined TNFa and FII productionand increased levels of tissue damage markers of AMI as well cen-
tral molecules for clotting processes, suggest that a complex genet-
ic background, might be involved in susceptibility to AMI in young
men and in the extension and severity of the disease.
In conclusion our data might prompt an approach to deﬁning
individual risk proﬁles that can be applied to healthy subjects to
predict intrinsic risk of AMI with different ages at onset. Such risk
proﬁles, when better established in a larger cohort of patients, can
be used to trigger further diagnostic procedures and early thera-
peutic interventions aimed at preventing or signiﬁcantly delaying
the clinical manifestations of cardiovascular disease.Acknowledgments
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